ClinicalTrials.gg

Program

lutropin alfa

Also written as “Follitropin alfa/lutropin alfa (MBJ-0011)”, “Follitropin alfa/lutropin alfa” and “Luveris”.

Its studies are mostly in Infertility · Hypogonadism, led by Merck KGaA, Darmstadt, Germany.

Furthest: phase 4, since May 20, 20069 company-led studies, 1 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany91 open or runningphase 4since May 20, 2006May 20, 2006Sep 30, 2027phase 3 · NCT07340827

Also a collaborator on its studies: Merck Serono Middle East FZ, Merck, S.L., Spain and Merck Pte. Ltd., Singapore.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2006First study: phase 4 study in HypogonadismFirst studyNCT00328926 · 11 enrolled · United States
  2. Feb 24, 2010Phase 2 study in InfertilityNCT01075815 · 76 enrolled · Spain
  3. Mar 2, 2010Phase 2 study in InfertilityNCT01079949 · 93 enrolled · Spain
  4. Mar 4, 2010Phase 3 study in HypogonadismNCT01084265 · 31 enrolled · China
  5. May 10, 2010Phase 3 study in InfertilityNCT01121991 · 55 enrolled
  6. Dec 20, 2011Phase 3 study in InfertilityNCT01497197 · 174 enrolled · United Arab Emirates
  7. May 19, 2021Phase 1 study in InfertilityNCT04899193 · 72 enrolled · China
  8. Nov 17, 2025Phase 1 study in InfertilityNCT07269327 · 24 enrolled · United Kingdom
  9. Jan 6, 2026Phase 3 study in InfertilityNCT07340827 · 266 planned · Japan

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in InfertilityNCT07340827

TargetBeta

LHCGR →read by rule
“Luteinizing hormone/Choriogonadotropin receptor agonist”ChEMBL 37, by rule

Other programs on LHCGR

ProgramCompanyFurthest phaseStudies
Chorionic GonadotropinruleOrganonphase 44

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07340827Infertility · Japan3RecruitingSep 30, 2027266
NCT07269327Infertility · United Kingdom1CompletedMar 9, 202624
NCT04899193Infertility · China1CompletedMay 28, 202272
NCT01497197Infertility · United Arab Emirates3TerminatedJan 2014174
NCT01121991Infertility3CompletedSep 200555
NCT01084265Hypogonadism · China3CompletedDec 200531
NCT01079949Infertility · Spain2TerminatedOct 201093
NCT01075815Infertility · Spain2TerminatedOct 201076
NCT00328926Hypogonadism · United States4TerminatedMay 201211

How it is read

Names in the registry

  • “Follitropin alfa/lutropin alfa (MBJ-0011)”, 1 entry
  • “Follitropin alfa/lutropin alfa”, 1 entry
  • “Luveris”, 1 entry
  • “Luveris®”, 1 entry
  • “r-hLH + r-hFSH”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.